Weave price target raised to $20 from $17 at Raymond James

Raymond James raised the firm’s price target on Weave (WEAV) to $20 from $17 and keeps a Strong Buy rating on the shares. Weave’s Q4 results showed normal quarterly upside with a similar moderating growth and incremental margin outlook vs. a year ago, the analyst tells investors in a research note. Shares could be under pressure on Friday, there were several optimistic updates supporting the firm’s positive stance, including greenshoots around its newest specialty medical vertical, the firm says.